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Controversies and dilemmas in the treatment
of malignant pain
According to the definition of the International Association for theStudy of Pain (IASP), pain is noticeably uncomfortable and emo-
tional experience, combined with actual or potential tissue damage, or
described at the time of such damage (1). The pain is extremely un-
pleasant emotional experience that is described as one of the oldest phe-
nomena of human life. It is a completely subjective experience, which
depends on personal perception of the pain. Making proper attitude
about pain is under various cultural, ethnic and linguistic influences,
and therefore the pain has a subjective component as well as multi-di-
mensional.
Patients are often unable to adequately evaluate pain (2). Also, they
are often prone to the denial of pain (3). The reasons are multiple, such
as denial of illness, fear that pain means deterioration of illness, belief
that »suffering« of pain »strengthens their« spirit, etc. In countries with
dominant Catholic religion, there is particularly strong belief in the suf-
fering and voluntary acceptance of pain. On the other hand, there is ev-
idence that medical staff underestimated the patient’s pain, and experi-
ences it less severe than it is presented by the patient. The big issue in
the assessment of pain is the lack of objective biological markers for
pain. Often, the only tool to detect the occurrence of pain or change in
intensity of pain remains a patients’ behavior tracking. Mood swings,
agitation, restlessness, insomnia, fatigue, depression or irritability are
some of signs that can draw attention to the occurrence of pain.
Treatment of pain is based on the guidelines adopted by the IASP
(International Association for or the Study of Pain) 2005. year (4). De-
spite the existence of guidelines pain treatment is extremely complex,
with a lot of dilemmas and controversies that are already reflected in
drug selection and decisions about how to implement the therapy of
pain.
In the treatment of cancer pain use of corticosteroids is common, al-
though the number of studies is too small to safely confirm their effec-
tiveness (5). Their use in practice has shown to have powerful anti-in-
flammatory effect, to raise the mood and appetite and that are useful in
the treatment of specific pain syndrome (reduction of intracranial pres-
sure, reduction of compression of the nerves, etc) (6, 7). With their ap-
plication it is possible to reduce the dose of opiates that are needed for
the reducing of pain. In treating pain it is extremely important to
achieve prompt elimination of pain or if it is impossible, to relieve feel-
ings of pain which is successfully achieved with corticosteroids. How-
ever, the use of corticosteroids has serious side effects which make big
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tradition and the unchecked statements. Existing studies
are too old, with too small number of patients, and poorly
designed. Further scientific research will give us proof
whether corticosteroids really have an impact in the
treatment of pain or it is a mistake. Until then, their use
remains open to options and decisions about their use as
a personal choice. In doing so, we must take into account
how long it will be used corticosteroid therapy, what dose
would be applied and what are the possible side effects of
the therapy in certain patients.
Next dilemma we face in treating cancer pain is opioid
rotation (9). We use opioid rotation when we’re not satis-
fied with pain control, and the patient has distinct side
effects of used drug. Opioid rotation helps to avoid severe
side effects and better pain control. (10). Opponents of
opioid rotation consider that opiates should not be viewed
as the sole treatment for pain, but greater importance
should be given to use of co-analgetics, adjuvant drugs
and psycho stimulants (11).
Particular problem is pain in the elderly population
(12). Older people rarely acknowledge the pain, harder
describe pain and its characteristics (13). Big part of el-
derly patients have sensory and cognitive impairments,
and sometimes they are unable to express the pain they
suffer. Therefore, absence of pain reporting must not be
accepted as a »no pain« state, and we should examine
whether a patient suffers pain.
In addition to sensory and cognitive disorders charac-
teristic of older populations and co-morbid diseases, are of-
ten multiple. Heart failure, coronary heart disease, general-
ized atherosclerosis, diabetes, and stroke are just some of the
conditions that frequently occur in the elderly population.
Co-morbid diseases must be treated in parallel with the
treatment of pain. Consequently the number of side effects
is greater, and their interpretation more complicated. It is
necessary to avoid polipragmacism and good knowledge of
the mechanisms of action of drugs is required to not harm
the patient. Also in elderly patients is necessary to take into
account the reduced renal and liver function, which does
not necessarily have to be manifested as abnormal labora-
tory findings. Therefore, identification and treatment of
pain in these patients is real challenge (13).
All known treatment options of pain are in accor-
dance with the moral principles of the Hippocratic Oath
(14). What are inconsistent with the Hippocratic Oath is
to use a placebo rather than medication. However, the re-
sults obtained using placebos in practice are often en-
couraging and represent a major ethical dilemma for any
doctor. By definition, a placebo is a substance or proce-
dure that is objectively without specific activity for the
state that is trying to heal (16). It has been scientifically
proven that the patient’s recovery can be accelerated if
the patients suggest improvement of his condition. The-
refore, a placebo may be part of the treatment of pain or
treatment of anxiety. Placebo action is manifested through
the placebo effect that was first scientifically confirmed in
1978 year (17). Advances in medicine and the use of
functional brain images using magnetic resonance imag-
ing proved that the use of placebo, leading to activation
and increased correlation between these parts of the brain:
area cingulata, prefrontal, orbitofrontal, and insular cor-
tex, nucleus accumbens, amygdala, periaqueductal gray
matter and spinal cord (18).
Prefrontal area of the brain could be responsible for
reminding the patient that he took a placebo, and thus
lead to a cognitive understanding of his work. Anterior
area cingulata and its effect on subcortical structures
could be associated with an expectation of a potentially
painful stimulus (18).Placebo effect depends on how it is
presented. A substance that acts as a muscle relaxant if it
is presented in another way it can achieve the effect of
muscle tension (19). Furthermore, the placebo effect de-
pends on whether the patient believes in the effect of sub-
stance that he receives. The length of the placebo effect is
different. As a remedy for panic disorders placebo can be
effective over 8 weeks, 6 months for angina pectoris and
even two and a half years as an analgesic in rheumatoid
arthritis (20). Placebo effect after verbal suggestions for
mild pain may be much stronger and last even after ten
applications. Placebo effect is not the same in all patients,
which is not surprising because neither effect a real cure
is not always the same in all patients (21). The applica-
tion of placebo in terms of analgesia will cause a positive
response in 35% of patients. Almost the same percentage
(36%) of patients will respond to therapy with low to me-
dium doses of morphine (4–8 mg) (22). The use of pla-
cebo in the treatment of pain has shown that the result is
better as the pain intensified (23). Usage of placebo ex-
tends period of time through which patients can support
pain. According to the VAS scale with use of placebo pa-
tients will feel pain lower by 2 to 5 point (24). However,
the use of placebo is morally, ethically and scientifically
questionable. Basically, usage of the placebo is deception.
It undermines honest relationship and trust between
doctor and patient which make an extremely important
link in the treatment.
Giving a placebo instead of drug is unethical and in-
terfere with the Hippocratic Oath which all doctors swear.
Consciously giving placebos to patients for a condition
that can be adequately treated, which prejudice the right
of patients to the best care possible, opens up many bio-
ethical issues. After all, how do we know which patient
will respond to placebo? Those who do not respond will
be subjected to unnecessary pain which is unacceptable.
Special entity is treating malignant pain at home. It is
substantially different from treatment in hospitals or in
hospices (25). Taking care for such a patient is within the
domain of family physicians and palliative care team.
Treatment is based on the basic principles of supportive
and palliative medicine, which means quickly and effec-
tively remove the pain, the treatment of »total« pain and
pain treatment plan (26). As is often performed on pa-
tients who are in poor physical and mental condition and
not able to make independent decisions the application
of ethical principles of autonomy is often questionable,
and sometimes impossible (27).
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In conclusion we can say that the treatment of pain in
oncology patients is a great professional challenge. Nu-
merous treatment options that exist, makes often deci-
sion more difficult. Insufficient number of scientific stu-
dies on pain, its pathophysiological mechanisms and
cause-effect situations to which it leads, raises practical
and ethical dilemmas. Notwithstanding all mentioned
nothing can prevent us to provide to every patient the
best care possible and to eliminate their pain or if it is im-
possible to reduce it. It is allowed to use a wide range of
medicines and methods, with adherence to ethical prin-
ciples and rules.
Numerous scientific studies on the mechanisms and
treatment of pain, and clinical observations will certainly
lead to changes and updates guidelines for pain manage-
ment on a global level (IASP 2005). We believe that a
number of controversies and dilemmas in the treatment
of pain to be elucidated. However, some will remain
within the limits of vague areas that the doctors involved
in treating pain put dilemmas and challenges. Therefore,
we have a duty and obligation to communicate our expe-
riences and reflections so that future guidelines for the
treatment of pain were more comprehensive.
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